The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

The Globe and Mail has
updated our Stock Quote Pages
You are about to experience the newly designed Stock Quote Pages format. With the new layout, you'll enjoy a more in-depth look at the companies you're following and pages that are easier to navigate. This Editors' blog post explains why we've made these changes.

 

AstraZeneca PLC

NYSE: AZN
Last

(U.S.) $64.64

Today's change0.00 0.00%
Updated July 1 4:00 PM EDT. Delayed by at least 15 minutes.
 

AstraZeneca PLC

NYSE: AZN
Last

(U.S.) $64.64

Today's change0.00 0.00%
Updated July 1 4:00 PM EDT. Delayed by at least 15 minutes.

AstraZeneca PLC closed at (U.S.)$64.64.

Over the last five days, shares have lost 2.84% and sit 2.25% above their 52-week low. This security has underperformed the S&P 500 by 18.86% during the last year.

Key company metrics

  • Open(U.S.) $64.78
  • Previous close(U.S.) $64.64
  • High(U.S.) $64.82
  • Low(U.S.) $64.37
  • Bid / Ask-- / --
  • YTD % change-8.16%
  • Volume2,134,549
  • Average volume (10-day)2,080,564
  • Average volume (1-month)1,573,483
  • Average volume (3-month)1,343,694
  • 52-week range(U.S.) $63.22 to (U.S.) $76.57
  • Beta0.71
  • Trailing P/E63.93×
  • P/E 1 year forward15.13×
  • Forward PEG4.88×
  • Indicated annual dividend(U.S.) $2.80
  • Dividend yield4.33%
  • Trailing EPS(U.S.) $1.01
Updated July 1 4:00 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+4.98%

Based on its net profit margin of 4.98%, AstraZeneca PLC is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.44%Sector:Industry:
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q1/2015Q4/2014Q3/2014Q2/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedMar 31, 201503/31/2015Dec 31, 201412/31/2014Sep 30, 201409/30/2014Jun 30, 201406/30/2014
Revenue6,0576,6836,5426,454
Total other revenue--------
Total revenue6,0576,6836,5426,454
Gross profit4,8315,0515,1845,173
Total cost of revenue1,2261,6321,3581,281
Total operating expense5,1247,0326,0015,345
Selling / general / administrative2,4583,0662,7672,650
Research & development1,2801,3601,2751,208
Depreciation / amortization265306342267
Interest expense (income), net operating--------
Unusual expense (income)3211,027515417
Other operating expenses, total-426-359-256-478
Operating income933-3495411,109
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax678-580322866
Income after tax552-321253797
Income tax, total126-2596969
Net income550-321254796
Total adjustments to net income--------
Net income before extra. items550-321254796
Minority interest-201-1
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items550-321254796
Inc. avail. to common incl. extra. items550-321254796
Diluted net income550-321254796
Dilution adjustment0------
Diluted weighted average shares1,2651,2621,2641,264
Diluted EPS excluding extraordinary itemsvalue per share0.43-0.250.200.63
Dividends per sharevalue per share0.001.900.000.90
Diluted normalized EPSvalue per share0.840.820.781.12